The United Kingdom and the United States have finalized a important commercial pact that will maintain no import taxes on UK drug shipments being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to raise expenditure on medicines through the National Health Service (NHS). This commitment ensures that import taxes on these key goods will stay at zero for a duration of the next three years.
This deal follows previous threats to significantly raise import taxes on branded drug imports, with increases discussed reaching 100%.
"This deal between the Britain reinforces the global environment for new treatments and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement said.
Trade Impact
Pharmaceuticals are one of the the United Kingdom's most significant exports to the United States, which is easily the biggest buyer for major UK drugmakers.
Statistics reveal that in the one-year period prior to September, the UK exported drugs totaling over eleven billion pounds to the US. This amount represented 17.4% of total UK exports in that span.
"This guarantee protects employment, increases investment and sets the stage for the UK to become a worldwide center for biotech and pharma," a government official commented.
Specific NHS Changes
The deal entails several key changes from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to double overall public funding on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must return to the NHS to stay within budget will be restricted at fifteen percent. Previously, repayments topped twenty percent.
Industry Background
The pact takes place against a long-running tension between the drug companies and the UK government over spending levels and approval rates.
The disagreement were exacerbated by assertions that US customers were paying significantly more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar investments have been announced toward projects in the United States.
One official publicly accepted that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a percentage of its resources over the last ten years.
